Pfizer (NY:PFE)

27.41 -0.39 (-1.40%)

Official Closing Price Updated: 7:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

99 100 Next >

The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts

February 05, 2026

In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a...

Via MarketMinute

Topics Earnings Economy

Pfizer (PFE) Q4 2024 Earnings Call Transcript ↗

February 05, 2026

Pfizer (PFE) Q4 2024 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Pfizer (PFE) Q3 2024 Earnings Call Transcript ↗

February 05, 2026

Pfizer (PFE) Q3 2024 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Pfizer Maps Post-Covid Reset With Obesity Trials And Deep Cost Cuts ↗

February 03, 2026

Via Talk Markets

Pfizer Reports Positive Weight-Loss Trial Results, Strong Q4 – So Why Is PFE Stock Falling? ↗

February 03, 2026

Via Stocktwits

Pfizer Inc. (NYSE:PFE) Beats Q4 2025 Estimates but Muted Outlook Tempers Investor Reaction ↗

February 03, 2026

Via Chartmill

Pfizer (PFE) Q2 2025 Earnings Call Transcript ↗

February 05, 2026

Pfizer (PFE) Q2 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings World Trade

Trump Administration To Launch TrumpRx Platform For Discounted Drugs Later On Thursday: Reports ↗

February 05, 2026

The medications that will be offered via the platform include Novo Nordisk’s popular weight-loss drug Wegovy, Eli Lilly and Company's Zepbound, Amgen’s cholesterol drug Repatha, and Merck’s diabetes...

Via Stocktwits

Topics Economy Government World Trade

Men's Health Network Launches "My Cancer, My Plan" Podcast on World Cancer Day

February 05, 2026

Via PRLog

Topics Death

The $1 Trillion Apothecary: A Deep-Dive Research Report on Eli Lilly (LLY)

February 05, 2026

As of February 5, 2026, Eli Lilly and Company (NYSE: LLY) stands as a paradigm-shifting titan in the global healthcare landscape. Having recently crossed the historic $1 trillion market capitalization...

Via Finterra

Topics Earnings Economy Intellectual Property

Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party? ↗

February 05, 2026

Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.

Via The Motley Fool

These S&P500 stocks are the most active in today's session ↗

February 04, 2026

Via Chartmill

Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 ↗

February 04, 2026

Eli Lilly is riding the GLP-1 gravy train, while this competitor is struggling to get on board.

Via The Motley Fool

AI Panic Hits Software, PayPal Faceplants, Walmart Joins the $1T Club ↗

February 04, 2026

Via Chartmill

Topics Artificial Intelligence

PFE Q4 CY2025 Deep Dive: Obesity Pipeline and Cost Discipline Face Post-COVID Headwinds

February 04, 2026

Global pharmaceutical company Pfizer (NYSE:PFE) beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 1.2% year on year to $17.56 billion. The company expects the full year’s revenue...

Via StockStory

Topics Intellectual Property

Will the Market Crash in 2026? Here's What History Says and What to Do About It ↗

February 03, 2026

Always be prepared.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

3 Unprofitable Stocks with Questionable Fundamentals

February 03, 2026

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.

Via StockStory

Topics Electric Vehicles

Bristol-Myers Squibb Earnings: What To Look For From BMY

February 03, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results this Thursday before the bell. Here’s what to expect.

Via StockStory

Why 2026 Could Be the Year Pfizer's Stock Finally Takes Off ↗

February 03, 2026

The company expects to launch more than 20 pivotal late-stage trials this year.

Via The Motley Fool

Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. ↗

February 03, 2026

Via Chartmill

Most active stocks in Tuesday's session ↗

February 03, 2026

Via Chartmill

Rigani Press Announces BioCT's Inaugural Book Event Featuring Dr. S. Yin Ho

February 03, 2026

Via PRLog

Topics Artificial Intelligence

Pfizer (PFE) Q4 2025 Earnings Call Transcript ↗

February 03, 2026

Pfizer (PFE) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Why Pfizer Stock Dropped Today ↗

February 03, 2026

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

Via The Motley Fool

Topics Earnings

Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops ↗

February 03, 2026

Pfizer reported strong mid-stage weight loss trial results for its monthly obesity drug and posted fourth-quarter earnings that beat analyst estimates, signaling progress in its obesity pipeline.

Via Benzinga

Pfizer Dives After Reaffirming Its Modest Outlook And Providing An Obesity Update ↗

February 03, 2026

Pfizer stock tumbled early Tuesday after the drugmaker reaffirmed its modest outlook for 2026 and provided an obesity update.

Via Investor's Business Daily

These S&P500 stocks are moving in today's pre-market session ↗

February 03, 2026

Via Chartmill

Pfizer (NYSE:PFE) Posts Better-Than-Expected Sales In Q4 CY2025

February 03, 2026

Global pharmaceutical company Pfizer (NYSE:PFE) announced better-than-expected revenue in Q4 CY2025, but sales fell by 1.2% year on year to $17.56 billion. The company expects the full year’s revenue...

Via StockStory

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

February 03, 2026

From Pfizer Inc.

Via Business Wire

Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial

February 03, 2026

From Pfizer Inc.

Via Business Wire

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.